• Lawyers in Sydney
• Lawyers in Melbourne
• Lawyers in Brisbane
• Lawyers in Perth
• Family lawyers
• Employment lawyers
• Criminal lawyers
• Wills and estates lawyers
• Find a lawyer

1. The offender, Mr Thomas Eric Kelleher, is to be sentenced in relation to the following offences, having entered pleas of guilty on 23 April 2025: (a) Count 1 (CAN2023/12129) – Supply anabolic steroids, contrary to s 171(2) of the Crimes Act 1900 (ACT), which has a maximum penalty of 500 penalty units, 5 years of imprisonment or both. (b) Count 2 (CAN2023/12139) – Supply declared substance, contrary to s 26(1) of the Medicines, Poisons and Therapeutics Goods Act 2008 (ACT), which has a maximum penalty of 500 penalty units, 5 years of imprisonment or both. (c) Count 3 (CAN2023/12513) – Traffic in large commercial quantity of a controlled drug, namely psilocine, contrary to s 603(1) of the Criminal Code 2002 (ACT), which has a maximum penalty of imprisonment for life. (d) Count 4 (CAN2024/8066) – Traffic in large commercial quantity of a controlled drug, namely tetrahydrocannabinol (THC), contrary to s 603(1) of the Criminal Code 2002, which has a maximum penalty of imprisonment for life. (e) Count 5 (CAN2024/12151) – Fail to comply with an order under s 3LA, contrary to s 3LA(6) of the Crimes Act 1914 (Cth), which has a maximum penalty of 600 penalty units, 10 years of imprisonment or both.

2. The offender has asked for the following additional offences to be taken into account in making a sentence-related order for CAN2023/12129, pursuant to part 4.4 of the Crimes (Sentencing) Act 2005 (ACT): (a) SC CAN2025/223: on 8 December 2023, money laundering, contrary to s 114B of the Crimes Act 1900, which attracts a maximum penalty of 1000 penalty units, 10 years of imprisonment or both. (b) CC2023/12150: on 8 December 2023, possess a prohibited weapon, contrary to s 5 of the Prohibited Weapons Act 1996 (ACT), which attracts a maximum penalty of 500 penalty units, 5 years imprisonment or both.

History of the proceedings

3. The sentencing proceedings commenced before me on 1 October 2025. On that day, I reserved my determination and the matter was listed on 17 October 2025 for the sentence to be imposed.

4. On 17 October 2025, the offender sought an adjournment of the sentencing proceedings on the basis that an application to re-open the proceedings and adduce further evidence was contemplated. The adjournment was not opposed.

5. On 11 March 2026 I heard an application by the offender to re-open the sentencing proceedings. The application was not opposed and it was granted. Counsel for the offender, Mr Purnell SC tendered an assessment from psychologist Ms Leesa Morris. Further evidence was led from the offender’s partner, Ms Frank (a pseudonym) and the offender himself gave evidence.

Agreed facts

6. For a period in 2023, the offender was a participant in a sophisticated illicit business that sold anabolic steroids, as well as pharmaceutical and illicit drugs, to customers across Australia via Australia Post.

Overview of the OzPharmlabs syndicate

7. Michael Kustic and the offender knew each other through the gym. For years, both had been users of anabolic steroids and regular users of illicit drugs.

8. Mr Kustic was the boss of the syndicate.

9. Co-offender Kustic operated the OzPharmlab Threema1 handle through which customers would make contact with the syndicate. He was also in charge of arranging the re-supply of the syndicates stock and paying other members of the syndicate a 'wage'.

10. The offender stored the illicit stock in his garage [redacted] in O'Connor. This was the warehouse out of which the group operated. The offender would pack the orders there before they were posted in street mailboxes.

11. Co-offender James Martens was a 'runner'. Co-offender Martens went by the nickname "Thirty" and his main job was to pick up deliveries from fraudulently obtained post office boxes as well as post the packed orders.

12. On occasion co-offender Martens also packed orders, packed pills into bottles, and made at least one run to Melbourne to pick up stock and deliver it to the hub at [redacted].

13. Day-to-day operation of the business and communications between the members of the syndicate happened over various Threema group chats.

14. Customers paid by either depositing money into bank accounts operated by co-offender Kustic or through cryptocurrency. The business and personal bank accounts operated by co-offender Kustic had been fraudulently opened in other people's names and through using identification material belonging to other persons.

15. Once payment was received from an OzPharmlabs customer, the salesmen would send through the orders to co-offender Kustic and the offender on Threema. The orders would be packed at [redacted] before being posted in street mailboxes.

16. Co-offender Kustic also maintained multiple post office boxes fraudulently opened in other people's names into which deliveries would be received.

Supply anabolic steroids

17. On or around 26 October 2023, an AFP covert operative placed an order and deposited $440 into the nominated account. The offender packaged and sent the order via post that was ultimately collected by Senior Constable Teagan McClure. The items sent were: (a) 2 x vials of Nexnos Pharma brand "Test 325" (b) 2 x vials of Nexnos Pharma brand Trenbolone Enanthate These items contain anabolic steroids.

18. On or around 9 November 2023, an AFP covert operative placed an order and transferred $350 into a nominated cryptocurrency wallet. The offender packaged and sent the order via post that was ultimately collected by Senior Constable Owen Patterson. The items sent were: (a) 1 x vial of OzPharmlabs branded Testosterone Sustanon (b) 100 OzPharmlabs branded Proviron tablets (c) 1 x vial of OzPharmlabs branded Testosterone Propionate These items contain anabolic steroids.

19. On or around 10 November 2023, an AFP covert operative placed an order and deposited $200 into the nominated account. The offender packaged and sent the order via post that was ultimately collected by Senior Constable Teagan McClure. The item sent was: (a) 1 x bottle of 100 Nexnos Pharma brand Anavar tablets This item contains anabolic steroids.

20. On 14 November 2023, co-offender Martens attended the offender's address at [redacted]. A short time later he left and drove to the post boxes on Sullivan Creek Road at ANU. Martens posted 42 packages into both the red and yellow post boxes.

21. With the help of Australia Post, police accessed the post boxes and identified several parcels suspected to have been posted by co-offender Martens. The parcels were taken to a sorting facility in Mitchell and were later seized by police.

22. The packages were addressed to different people across Australia and labelled as coming from businesses, such as the Parramatta Tackle Shop. Most of the parcels contained anabolic steroids and declared substances. A list of the substances contained within packages seized is found at Annexure A.

23. Two of the packages each contained 15 bars of 'PSI' branded chocolate cookies, totalling 30 bars. These chocolate cookies were described to contain '4G PSILOCYBIN MUSHROOMS'. The total weight of the bars was approximately 1.62 kgs. Analysis confirmed the product to contain the controlled drug Psilocin.

24. Also amongst the 42 parcels was 2 bags of a product described as 'Bliss Bites Watermelon' with the further description, 'Premium infused THC Gummies'. The following picture depicts the packaging of these two products:

25. The same product was later seized during a search warrant at Westgarth Street and confirmed by analysis to contain the controlled drug THC.

26. The offender was involved in the packaging and distribution of the packages seized on 14 November 2023 (as per his role described above).

27. On or around 21 November 2023, an AFP covert operative placed an order and transferred $540 into a nominated cryptocurrency wallet. The offender packaged and sent the order that was ultimately collected by Senior Constable Owen Patterson. The items sent were: (a) 1 x Primobolan 100 (b) 1 x NPP 100 (c) Dianabol These items contain anabolic steroids.

28. On or around 30 November 2023, an AFP covert operative placed an order and transferred $540 into a nominated cryptocurrency wallet. The offender packaged and sent the order that was ultimately collected by Senior Constable Damian Clark. The items sent were: (a) 2 x vials of OzPharm Labs branded Test C 200 (b) 2 x vials of OzPharm Labs branded Tren E 200 (c) 2 x vials of OzPharm Labs branded Equipose 250 These items contain anabolic steroids.

29. On 7 December 2023, the offender picked up a white package from Curtin post office. He then drove to Deakin post office where he posted packages in the street mailing box.

30. With the assistance of Australia Post, police immediately accessed the mailbox and, once a warrant was obtained, seized the 31 packages that had been posted by the offender.

31. The parcels were addressed to different people and were labelled as coming from shops such as "tackle and reels". The parcels primarily contained OzPharmlabs branded anabolic steroids and declared substances. One package contained a bottle of "Quattro" CBD oil. Analysis confirmed this product to contain THC. The same product was later seized during a search warrant at [redacted] and confirmed by analysis to contain the controlled drug THC. A list of the substances contained within the packages seized is found at Annexure B.

Photograph of one of the parcels posted by the offender

Search warrants

32. On 8 December 2023, police executed search warrants at multiple properties connected to the syndicate.

33. At [redacted], where the offender lived and which was the packing and distribution hub of the business, police found and seized over two days- (a) Significant number of boxes of anabolic steroids and pharmaceutical drugs; (b) 40 blocks (a total weight of 2.14 kgs) of 'PSI' branded mushroom chocolate bars containing Psilocin. 30 of the chocolate bars were located in a fridge within the garage; (c) Numerous items containing THC (a total weight, including additives, of over 21 kgs); (d) $66,095 in cash; (e) Oleoresin capsicum spray; (f) Cryptocurrency hardware wallets and cryptocurrency; (g) Two Ford Ranger vehicles and a Harley Davidson motorcycle; and (h) Australia post parcel packages.

Photograph of the offender's garage

34. The total street value of the drug items seized, based on prices advertised by OzPharmLabs during the controlled buys, is $8,301,430. A list of the substances contained within packages seized is found at Annexure C.

35. The offender's DNA and fingerprints were found on a number of items within the garage.

36. During the execution of the warrant, the offender failed to comply with a s 3LA order in relation to a laptop and mobile phone.

Nature and circumstances of the offending

37. The offences capture the offender’s participation in a commercial drug enterprise which operated under the name “OzPharmLabs” and involved the sale online and through encrypted communication services of anabolic steroids, pharmaceutical and illicit drugs. The maximum penalties which apply to the offences, as a yardstick, reflect the seriousness of the conduct. Two of the offences have a maximum penalty of imprisonment for life.

38. The factors relevant to an assessment of the objective seriousness of drug trafficking were set out by the Court of Appeal in Bui v The Queen [2015] ACTCA 5. I consider those factors also usefully inform an assessment of the offences which involved the supply of anabolic steroids and declared substance. The Court observed at [41]: The role of the accused is an important consideration, those whose level in the operation is at a higher level of the hierarchy being more culpable: MacDonnell (2002) 128 A Crim R 44 at 50; While, as decided in Wong v The Queen at 609; [67]-[70], the weight of the amount of drug is not of chief importance in determining the appropriate sentence, it remains a relevant factor, particularly in the context of the harm from its distribution effects: R v Bezan (2004) 147 A Crim R 430 at 438; The motivation for the offence is highly relevant, the purpose of profit being a more serious matter: R v Speechly (2002) 133 A Crim R 26 at 30; R v Day (1998) 100 A Crim R 275 at 277.

39. There was no evidence before me as to the purity of any of the substances involved. Purity of a drug can be a relevant consideration though it is not as simple as the lower the purity, the less objectively serious the offending. While purity can indicate where an offender is in the supply chain of a drug enterprise, in this matter there are other considerations which sufficiently establish the extent of the offender’s role in the enterprise.

40. The prosecution conceded two aspects of the trafficking offences relevant to consideration of their objective seriousness and of the significance of general deterrence and community protection. First, that the offences involved drugs with a capacity for profit which was not as financially rewarding as with other illicit drugs. Secondly, that the drugs involved did not have the same harmful effects on the community as other illicit drugs, such as methamphetamine.

41. These concessions are consistent with the approach taken by the Victorian Court of Appeal in DPP v Maxwell [2013] VSCA 50 where the court accepted that a “reward differential” as between substances could reasonably justify lower sentences for offending which involved substances yielding lower reward on the basis that it was a proper matter to consider with respect to culpability, further observing at [34]-[36]: Sentencing judges are also justified in treating the scale of the anticipated reward as relevant to considerations of deterrence, both specific and general. As has often been said, the sentence to be imposed for a drug importation (or trafficking) offence must signal both to the offender, and to other would-be offenders, that the potential financial rewards to be gained from such activities are outweighed by the risk of severe punishment. Obviously enough, the greater the anticipated reward, the more powerful the deterrent message must be. The converse is also true. There is another reason why general deterrence may be seen to be of increased importance if the anticipated reward from dealing in illicit drugs is high. Where the potential to reap large profits from dealing in a particular proscribed drug is great, the potential for the commission of offences involving that drug — with corresponding risk of harm to the community — might be regarded as greater. Thus, considerations of general deterrence and community protection are of more significance in those cases than in a case like the present. To treat a low-reward drug like GBL differently for sentencing purposes is in no way inconsistent with the statutory assumption that a commercial quantity of drug A is to be viewed for sentencing purposes as being just as harmful as a commercial quantity of drug B. But it is to recognise that the very high maximum penalties fixed for offences involving a commercial quantity (or more) reflect a legislative intention to visit very heavy punishment on drug profiteers. Plainly enough, KM does not fall into that category. (Citations omitted.)

42. With respect to the offence involving declared substances, the prosecution drew my attention to Ede v Hyde [2014] ACTSC 305 at [6] in which Penfold J observed the following with respect to offences committed pursuant to the Medicines, Poisons and Therapeutics Goods Act 2008: The relevant object furthered by the prosecution of Mr Ede seems to have been that set out in s 6(1)(c), to minimise “the diversion of regulated substances for abuse”. While some of the other specified objects of the MPTG Act are directly related to the safety of individual members of the public, the diversion of regulated substances for abuse seems to raise issues that are broader than just the direct dangers of unauthorised consumption of the relevant substances. Those issues may include such things as the danger possibly posed to the community by people who have consumed mind-altering drugs without a good medical reason, affecting the availability of the substances for legitimate use and effectively diverting any public subsidies incorporated in the price of medicines supplied on prescription.

43. Bearing those matters in mind, I make the following observations with respect to the features of the offending in this instance. Trafficking in a large commercial quantity of THC (CAN2023/8066) and psilocine (CAN2023/12513), supply anabolic steroid (CAN2023/12129), supply declared substance (CAN 2023/12139) The role of the offender

44. The offender’s role in the enterprise was important; the provision and organisation of his premises (as revealed in the search warrant footage) facilitated a critical step in the process of distribution. He was also involved in packaging and distributing. There can be no doubt that the offender was aware of the nature and scope of the operation in which he was participating.

45. The footage taken at the execution of the search warrant on his home revealed the nature and scope of the business in which the offender was engaged. In one large room of the home there was ceiling to floor shelving with numerous large plastic tubs containing the substances the offender was packaging for distribution. In the middle of the room were tables to enable sorting and packaging of the substances. The substances were supplied to ‘customers’ by post which was achieved by the inclusion in the room of large rolls of plastic wrap to secure the substances for successful distribution. The configuration of the room reflected a high level of organisation in support of a large-scale enterprise. There can be no doubt the configuration of the room reflected the deliberate and significant role of the offender in a well organised operation.

46. I cannot accept the submission made on the offender’s behalf that there was no basis to conclude that the THC and psilocine were part of the enterprise in which anabolic steroids and declared substances were being supplied. There was evidence that products containing THC and psilocine were found in packages which I am satisfied emanated from the offender’s premises.

47. I am satisfied beyond reasonable doubt that the two trafficking offences were committed in the context of the offender engaging in a sophisticated drug enterprise which involved trafficking in controlled drugs as well as supplying anabolic steroids and declared substances.

48. In DPP v Martens [2025] ACTSC 24 I sentenced a co-offender who I found was operating in the “OzPharmLabs” business as a “runner” who was “at the bottom of the chain” completing tasks for the offender and co-offender Kustic.

49. The scope and significance of the offender’s role is well above that of the offender in Martens. I accept that he was not a controlling mind at the very top of the enterprise and that he was operating at the direction of Mr Kustic. The prosecution accepted that the offender was not responsible for sourcing the controlled drugs or the substances being packaged and distributed from his home.

50. I am satisfied beyond reasonable doubt that the offender was substantially and deliberately involved in the drug enterprise at the mid-level of the operation.

Quantity and value of the trafficked drugs

51. The weight of the psilocine (admixture) was approximately 3.76 kilograms. This is almost double the large commercial quantity. The packaging indicated that there was 4 grams of the controlled drug (6.7% of the admixture). Purity was not analysed. The value of the product was $17,500.

52. The weight of the THC (admixture) was over 21 kilograms. This is ten times the large commercial quantity. Purity was not analysed. The value of the product was $78,000.

53. The prosecution in highlighting the significant weights involved in the trafficking offences, conceded that the commercial value and accordingly the potential for profit or ‘reward’, was relatively low in each case.

54. The value of the anabolic steroids was significant and estimated to be approximately $5.4 million.

55. The value of the declared substance was significant and estimated to be approximately $2.8 million.

Motivation for the offending

56. The offender frankly nominated that he was motivated by financial gain. The offender’s motivation for the offending was explored in the report of Ms Morris; a matter to which I will come.

Fail to comply with 3LA order (CAN2024/12151)

57. It was accepted this was an unremarkable example of the offence.

Scheduled offences to CAN2023/12129: money laundering (SC CAN2025/223) and possess prohibited weapon (CC2023/12150)

58. These offences are to be taken into account when making a sentence related order for the supply of anabolic steroids offence. The scheduling of offences will have the consequences of a longer sentence being imposed on the principal offence because of the effect on a consideration of the purposes of sentencing. Each scheduled offence in this matter was an objectively serious offence with significant maximum penalties (10 years of imprisonment for SC CAN2025/223 and 5 years of imprisonment for CC2023/12150). Each offence involved distinct conduct though was otherwise indicative of the overall nature of the enterprise in which the offender was participating.

Subjective circumstances

Pre-Sentence Report

59. A pre-sentence report (PSR) detailed that the offender was born in Wagga Wagga, NSW and moved to Canberra when he was 11 years old. He is one of four children and lived with his mother and three brothers for most of his childhood. The offender informed the report author that his early childhood was unstable. The offender left home at approximately 15 years old to live in a refuge, as he was unable to continuing living with his mother. He continued to live in refuges until he was 17 years of age.

60. He first met his father at 18 years of age and he has no relationship with him. The offender reported that he ceased contact with his mother 8 years ago due to her unaddressed mental health concerns. Similarly, the offender does not have a positive relationship with his siblings. The offender could not identify to the report author a family member in his life that could provide him support.

61. The offender and his ex-partner share a 19-year-old son who resides with the offender’s ex-partner full time. The offender reported regular contact with his son. The offender’s current relationship commenced 2 years ago, and he reported it to be positive. He noted his partner has experienced some mental health concerns resulting in relationship difficulties. He currently resides with this partner in their rental property.

62. The offender obtained apprenticeships in panel beating, spray painting and carpentry. He reported working in various trade positions and has worked as carpenter for over 20 years. His employment is his main source of income. He did not report any difficulty meeting his financial commitments.

63. The offender maintains pro-social connections with friends who have not been involved in any criminal activity.

64. The offender first consumed alcohol when he was 16 years old. He advised that his alcohol consumption drastically reduced following a conviction for drink driving and the birth of his son. He now only consumes alcohol occasionally. The offender first consumed illicit drugs when he was 12 years old his with brother and smoked cannabis multiple times a day from ages 14 to 20. He was abstinent from illicit substance use for a period of 16 years. He ceased drug use almost 2 years ago. He underwent two urinalysis tests during the preparation of the pre-sentence report, which returned negative results.

65. The offender reported that his offending was financially motivated after he accrued a $40,000 debt following a period of unemployment which arose from injuries sustained whilst powerlifting. He noted that the financial benefit he obtained from his offending has been outweighed by the consequences he is now facing. The offender accepted his actions were wrong.

66. The offender was assessed as being at a low risk of general reoffending due to his protective factors. The offender’s attitude towards the offending was described as positive given that he had taken responsibility for his conduct and did not attempt to minimise or justify his actions. The offender expressed willingness to undertake any recommended programs.

Intensive Corrections Order Assessment Report (ICOAR)

67. The offender was assessed as suitable for an intensive correction order and signed an undertaking to comply with the obligations of an intensive correction order.

Letter from the offender

68. A letter under the hand of the offender was tendered.

69. The offender’s letter briefly canvased his traumatic upbringing and noted that his mother’s partners would engage in acts of violence towards him. He described difficulty confronting and discussing this period of his life.

70. The offender described some of the effects of his offending. He explained that he discourages young adults he interacts with at his gym from steroid use. The offender ceased prescription steroid use about a month after he was released on bail.

71. The offender suggested that he understood the risk involved in supplying illicit drugs to the community, observing that the drugs could have “anything in them” and users may have adverse reactions. He acknowledged that his offending made a poor contribution to society and that he was living an ‘unhealthy’ life.

72. [redacted] The offender’s evidence: 11 March 2026

73. The offender confirmed that he lives at a rental property with his partner, Ms Frank. He is solely responsible for the payment of rent which is $690 per week, and he has a vehicle which costs him $150 per week. He is employed as a commercial carpenter with a construction company and works on a variety of projects. He has an annual salary of $100,000 and after tax earns $1600 to $1700 per week.

74. The offender detailed that the lease on his current rental property has twelve months remaining and he pays the rent a month in advance. The offender explained several challenges he faced in securing the rental property once charged with the offences, noting he was evicted from his previous property, and had limited success through real estate agents. He eventually secured his current property through a personal connection.

75. The offender explained that he has limited assets with which to continue to financially support his partner should he be sentenced to a period of full-time imprisonment. He also described his employment as stable though could not with certainty that it would be available for him to return to should he be incarcerated.

76. The offender confirmed he and his partner’s desire to start a family. He stated that “starting again” after a return to full time custody would be very difficult for him and he was unsure as to how he would go about it. The offender confirmed that he had no thoughts of returning to offending behaviour and that he does not associate with anyone from that period of his life.

77. Since October 2025, the offender has not sought to “get his affairs in order” because “everything is on hold”. He explained that he would need to sell his assets if he were sentenced to a period of full-time imprisonment. He agreed the market value for his current vehicle is around $20,000 and that he owes around $10,000 on that vehicle. He suggested he would have limited capacity to sell his large collection of carpentry tools. The offender agreed any profit realised from the sale of his vehicle, which he accepted would be at least $8,000, would go to his partner.

78. He agreed that he had successfully reintegrated back into the community after he was released on bail after his arrest and that it was likely that he would be re-offered employment with the same company which currently employs him if he were sentenced to a period of full-time imprisonment. The evidence of Ms Frank: 1 October 2025

79. The offender’s partner gave evidence consistent with many of the matters referred to in the offender’s letter. She was not subject to cross-examination. She considered the offender to be ashamed and embarrassed by his offending, and to be remorseful for his involvement in a drug enterprise. She affirmed her support for the offender and the high regard in which he is held by her family. She described her own significant mental health challenges and the support the offender provides to her, which includes that he is entirely responsible for their financial stability, including the payment of rent on the property where they currently reside. The evidence of Ms Frank: 11 March 2026

80. Ms Frank gave further evidence at the sentencing hearing on 11 March 2026.

81. Ms Frank explained that after the offender was arrested, she was admitted to a psychiatric facility due to a psychotic episode. She was subsequently declared medically unfit for work for 9 months after her release from that facility. She is now on a medically supervised return to work plan and working 28 hours per week in the public service. She described receiving an overpayment during a time when she was on medical leave. As a consequence, there is a payment plan in place for her to repay that debt.

82. She confirmed that she lives in a rental property with the offender and that he is responsible for the rental payment of $690 per week. She noted the offender pays “most of the bills”. She further explained the offender has a debt in relation to his vehicle for which he is solely responsible.

83. Ms Frank described the offender as the “structure and support she requires day to day”. The offender assists her with the management of her bi-polar disorder including with everyday tasks such as taking medication, eating well, sleeping and going to the gym. She takes medication with the offender’s assistance because it requires some monitoring so that she does not slip into a manic episode.

84. Ms Frank explained that she is 35 years old and understands that she has “low egg reserves”. She described that medical advice has suggested that she ought to start trying for a family or to freeze her eggs. She described understanding that there can “complications” for people with bi-polar and fertility treatment. She explained she has experienced long periods of poor mental health arising from bi-polar disorder, including “regular hospitalisations”.

85. Ms Frank asserted that she cannot afford to pay the rent on the current rental property without the offender, and she would have to move in with her mother who has cancer should the offender no longer be able to pay the rent. Ms Frank explained that accommodation with her mother is not a long-term option and that she has been informed by her ‘uncle’ that housing which might available to her through “Aboriginal housing” might take “years” to access. She did not identify any other option for accommodation which would be available to her.

86. Ms Frank said she expected to have trouble obtaining rental accommodation without the offender because of the effect of her medical history and the associated absence of a long-term rental history.

87. She described living a quiet life with the offender who has restricted his social circle.

88. In cross-examination, Ms Frank explained that she earns after tax $2800 per fortnight and estimated spending $200 per fortnight for repayments for the debt she has accured arising from overpayments. She has costs associated with a vehicle and medical treatment. She has private health insurance. She has some savings which she estimated to be $4000 which she has put aside for fertility treatment. She understands fertility costs may extend to $9000 and that her private health insurance may cover $3000-$4000.

89. Ms Frank accepted in cross examination that she has not assessed her financial circumstances in detail but maintained that it would be very difficult for her financially without the offender who pays all household bills.

90. After giving evidence, with the consent of the prosecutor, payslips for Ms Frank were provided. The demonstrated that Ms Frank has an annual salary of $108,360. She presently has a net income of $1855.93 per fortnight. A debt repayment plan requires her to make a payment of $200 per fortnight.

Character references

91. Two character references were tendered on behalf of the offender from his current employer and his ex-partner.

92. The offender’s current employer, Mr Sutherland noted that he has known the offender both personally and professionally for over a period of 10 years. He commended the offenders’ skills in his profession and his work ethic. He highlighted that the offender was quick to gain employment in the construction industry upon being released on bail and opined this demonstrates that the offender is in demand and trusted in the industry. Mr Sutherland described the offender as consistent, reliable and having positively contributed to worksite culture.

93. The offender’s ex-partner and the mother of his son has known the offender for 25 years. She acknowledged the charges before the court. His ex-partner considered the conduct of the offender to be out of character and described him as a reliable and positive presence in their son’s life. She stated that the period of remand was a difficult time for their son and that the offender did not wish for their son to visit him in custody, so to avoid exposing him to the prison environment. The offender had made clear to her and to their son, his regret, shame and embarrassment about his offending. Report of Ms Leesa Morris

94. Ms Morris assessed the offender on 18 November 2025. She confirmed his family history included exposure to drug abuse alcohol and domestic violence. The offender left home at 15 years of age and lived in a refuge for a period. He was supported to a degree by his paternal grandparents who died when he was 18 years of age. He attended over 15 different schools. The offender commenced regular alcohol use in high school and first consumed cannabis when he was 12 years of age. He used GHB (gamma-hydroxybutyrate) in his late teens and recommenced use when he was “selling drugs” after the breakdown of a long-term relationship and suffering an injury from a motor vehicle accident.

95. Ms Morris confirmed the offender’s stable history of employment and his current relationship with Ms Frank.

96. Ms Morris reported that the offender experiences intrusive memories of his childhood “without precipitant” and sleep disturbance. He reported being quick to anger. The offender considered that his childhood experience caused him to be “hyper independent. I don’t trust or rely on anybody. I always make sure I have money so I don’t have to depend on anyone”.

97. Ms Morris concluded that the offender met diagnostic criteria for complex post-traumatic stress disorder (CPTSD). The offender has experienced symptoms consistent with anxiety his whole life, including night-time rumination which affects his sleep.

98. Ms Morris considered that the offender presented with a significant trauma history that has resulted in a permanent psychological condition. At the time of his offending, the offender described a period of extreme stress that aggravated his psychological condition. As a consequence, the offender felt at risk of being unable to provide a sense of stability and safety for himself. The offender explained to Ms Morris that the time of the offending he was in financial distress after being unemployed for a year and the breakdown of his relationship. The offender told Ms Morris that “it was almost a relief when we got caught, it was just so busy”.

99. Ms Morris concluded that the offender is at a low/moderate risk of reoffending with his history of substance use largely driving that assessment. Ms Morris concluded that the most effective means of reducing the offender’s likelihood of reoffending would be his engagement with psychological intervention for his trauma condition. She suggested that this would require two years’ worth of therapy in a physically and emotionally secure environment.

100. Ms Morris recorded the offender’s role in Ms Frank’s life consistent with her own evidence in these proceedings. Ms Morris recorded that the offender’s concerns for Ms Frank should he be sentenced to a period of full-time imprisonment is likely to weigh heavily upon him in the custodial environment, added to which was the exacerbating effect that the custodial environment will have on the offender’s CPTSD.

Responsibility, remorse and rehabilitation

101. On the material before me I am satisfied that the offender has demonstrated remorse for his conduct and taken responsibility for his offending. The offender has demonstrated insight into the gravity of his offending and frankly accepted that he was driven by financial gain.

102. The presence of genuine remorse properly influences an assessment of an offender’s potential for rehabilitation. In addition to remorse, the offender has strictly complied with a regime of bail for a substantial period which significantly curtailed his liberty, including daily reporting to police.

103. In both the PSR and ICOAR, the authors noted that the offender has significant protective factors that guard against recidivism and will aid the offender in his rehabilitation. Specifically, the offender’s pro-social relationships, full-time employment and stable accommodation. I am satisfied that he is at a low risk of re-offending.

104. The offender had a childhood marked by disadvantage and disruption. A sentencing court is obliged to give a childhood experience of disadvantage “full weight” (see Bugmy v The Queen [2013] HCA 37; 249 CLR 571 at [44]). The prosecutor conceded that the conclusion contained in Ms Morris’ report that the offender’s traumatic background drove him to seek the safety and stability he perceived financial security offers, provides some explanation for the offender’s financial motivation for the offending. In this way, the offender’s background does explain his offending behaviour to a degree. I consider his moral culpability is reduced to an extent.

105. The offender’s difficult upbringing also informs his capacity for rehabilitation. Despite his childhood experience, prior to these offences he had for the most part achieved a measure of success and stability founded on full time employment and supportive relationships. His capacity to build such a life in the face of a deprived childhood experience demonstrates personal resilience and his capacity to live a law-abiding life. Indeed, the offender appears to have drawn on his resilience to re-build his life after his period on remand. He clearly has a very strong work ethic and a sought-after skill set in the building industry which makes him an attractive employee. It is significant that he does not present with any current issues connected with drug abuse.

106. The potential for high reward offered by the drug trade often brings with it the potential for disastrous consequences. If the offender did not appreciate that fact before his arrest, I am satisfied he does now. The offender’s poor decision to align himself with an organised drug enterprise disrupted what was otherwise a mostly law-abiding existence. His approach on bail reflects his understanding of the seriousness of his position, his significant capacity for compliance and his ability to be in the community without risking community safety.

107. I am satisfied the offender has very good prospects of rehabilitation.

Criminal history

108. The offender has a limited criminal history across New South Wales and the ACT. His criminal history disentitles him to significant leniency. His criminal history does not contain any entries for drug related offending.

Time in custody

109. The offender spent 4 months and 15 days in custody prior to the grant of bail. This period of pre-sentence custody will be taken into account in the sentence I impose.

Plea of guilty and assistance to authorities

110. The offender entered pleas of guilty to the offences on 23 April 2025, following negotiations after a criminal case conference on 14 April 2025. There is no reason to depart from the usual reduction that the timing of those pleas would attract: see Blundell v The Queen [2019] ACTCA 34 at [12]. A 20 per cent reduction in the sentence of imprisonment imposed is appropriate.

111. At the sentencing hearing the offender confirmed his willingness to give evidence consistent with the agreed statement of facts, which identified co-offender Kustic as the person to whom he reported, at the trial of co-offender Kustic. The prosecutor accepted that this was likely to be significant evidence in the prosecution of Mr Kustic. I consider an additional 10 per cent reduction pursuant to s 36 of the Crimes (Sentencing) Act 2005 is appropriate in those circumstances.

Sentencing practice

112. I bear in mind that sentencing statistics and comparable cases do not define the range of available sentences nor place a cap on the upper or lower ranges of a possible sentence. In this matter the controlled drugs subject to the trafficking charges are not commonly the subject of such charge. I have borne this in mind.

113. The prosecution took me to two sentencing outcomes which involved different substances and difference maximum penalties to those in this matter: DPP v O’Keefe [2024] ACTSC 210 and DPP v Mussa [2025] ACTSC 342. I have had regard to the observations I made in O’Keefe at [120]-[124] with respect to other sentencing outcomes.

114. In DPP v O’Keefe [2024] ACTSC 210 the offender prepared and packed 3.284 kilograms of cocaine and transported 4.1 kilograms of methylamphetamine. This offender was financially motivated arising from an addiction to illicit substances and was aware of the scope and nature of the drug operation. This offender was 35 years old with one relevant entry on his criminal history. He had excellent prospects of rehabilitation. The starting point for the offence of trafficking in a commercial quantity of a controlled drug, being cocaine, (which attracts a maximum penalty of 2,500 penalty units, 25 years of imprisonment or both) was three years and six months of imprisonment, reduced to three years and three months of imprisonment for the plea of guilty. The starting point for the same offence with respect to the trafficking of methylamphetamine was four years and six months of imprisonment. The offender was not entitled to any ‘significant’ reduction as the case against him was overwhelmingly strong. The aggregate sentence was 6 years of imprisonment. The offender had spent 8 days in pre-sentence custody. A non-parole period of 2 years and 10 months was imposed.

115. The matter of DPP v Mussa [2025] ACTSC 342, involved the co-offender of O’Keefe. The offender participated in the preparation and packaging of substances as well as managing the premises where the drugs were kept. The offender was financially motivated, had a limited criminal history and excellent prospects of rehabilitation. The starting point for the offence of trafficking in a commercial quantity of a controlled drug namely cocaine, (which attracts a maximum penalty of 2,500 penalty units, 25 years of imprisonment or both) was three years of imprisonment. The starting point for the same offence with respect to methylamphetamine was 3 years and 10 months of imprisonment. A 20% reduction in recognition of pleas of guilty was applied. The aggregate sentence was 4 years, four months and 24 days of imprisonment. The offender had spent 44 days in pre-sentence custody. A non-parole period of 22 months was imposed.

Parity

116. Parity is a consideration in this matter there being a co-offender. Neither offender should be left with a justifiable sense of grievance arising from the sentence I impose. Co-offender Martens did not have a substantial criminal history and received a total reduction of 40 per cent; 25 per cent in recognition of his plea of guilty and 15 per cent in recognition of his assistance to law enforcement authorities. The following sentences were imposed: (a) On the charge of trafficking in a commercial quantity of a controlled drug (CC2023/12170), namely psilocine, contrary to s 603(7) of the Criminal Code the offender was convicted and sentenced to 1 year, 9 months and 17 days of imprisonment commencing on 11 February 2025 and ending on 27 November 2026. This offence attracted a maximum penalty of 2,500 penalty units, imprisonment for 25 years or both. (b) On the charge of trafficking in a controlled drug other than cannabis (CC2023/12171), namely tetrahydrocannabinols (THC), the offender was convicted and sentenced to 1 year, 2 months and 11 days of imprisonment commencing on 11 February 2026 and ending on 21 April 2027. This offence attracted a maximum penalty of 1,000 penalty units, imprisonment for 10 years or both. (c) On the charge of supplying anabolic steroids (CC2023/12153), the offender was convicted and sentenced to 10 months and 23 days of imprisonment commencing on 28 November 2026 and ending on 20 October 2027. This offence attracted a maximum penalty of 500 penalty units, imprisonment for 5 years or both. (a) On the charge of supplying declared substances (CC2023/12163), the offender was convicted and sentenced to 10 months and 23 days of imprisonment commencing on 3 June 2027 and ending on 25 April 2028. This offence attracted a maximum penalty of 500 penalty units, imprisonment for 5 years or both (d) On the charge of dealing with the proceeds of crime (CC2024/7335), the offender was convicted and sentenced to 7 months and 5 days of imprisonment commencing on 26 November 2027 and ending on 30 June 2028. This offence attracted a maximum penalty of 1,000 penalty units, imprisonment for 10 years or both. (b) This is a total period of imprisonment of 3 years, 4 months and 20 days. I directed that the sentence of imprisonment be served by way of intensive correction order subject to the core conditions listed in s 42 of the Crimes (Sentence Administration) Act 2005 (ACT).

117. A further trafficking offence was taken into account with respect to both CC2023/12170 and CC2023/12171.

118. It is useful to recall the observations of the Court of Appeal in Thompson v The Queen [2018] ACTCA 2 at [24]: The notion that like cases should be treated alike is fundamental to any rational and fair system of criminal justice: Lowe v The Queen (1984) 154 CLR 606, 610–11 per Mason J. Unjustifiable disparity is an infringement of the equal justice norm: Green v The Queen [2011] HCA 49; 244 CLR 462 at [32] (Green). However, just as equal justice requires that like offenders should be treated alike, relevant differences should also be acknowledged: Postiglione v The Queen (1997) 189 CLR 295, 301–2 (Postiglione) per Dawson and Gaudron JJ. This approach to parity has been applied by this Court in many cases, including Singh v The Queen [2017] ACTCA 17 at [74], Rubino v The Queen [2015] ACTCA 22 at [26]–[27] and Le Clair v The Queen [2017] ACTCA 19 at [48] (Le Clair).

119. The offender’s role in the drug enterprise was substantially greater than that of co-offender Martens. The offender’s role was important to the success and reach of the syndicate consistent with the sophistication of the operation revealed in the video footage of the search warrant. Consistent with a significant role and the trust extended to him by the syndicate, the offender was responsible for storing and packing a highly valuable quantity of substances as part of an organised distribution chain.

120. Co-offender Martens was sentenced on the basis that he was a “runner” for the syndicate, and his role was entirely dispensable.

121. In Martens I accepted that the co-offender was driven to offend by the opportunity for financial gain in the context of the need to fund his own entrenched drug addiction. Unlike this offender, the co-offender Martens’ moral culpability was not reduced because of a disadvantaged childhood experience. The material difference as between their roles in the drug syndicate must be reflected in the sentenced imposed on the offender.

122. In Martens the prosecution did not oppose service of the period of imprisonment imposed by intensive correction order (ICO).

Determination

123. At the outset, counsel for the offender sensibly accepted that the only appropriate outcome is a period of imprisonment. I agree.

124. I am satisfied that specific deterrence has been achieved to a large degree and that the offender has very good prospects of rehabilitation.

125. A reduction in the offender’s moral culpability moderates the weight of general deterrence and punishment to some degree. Notwithstanding that finding, they remain compelling considerations. Involvement in the business of drug supply which fuels addiction and all the misery which accompanies it, must be denounced. The maximum penalties in this matter reflect the community’s intolerance for those who seek the rewards of drug trafficking and supply. Those like the offender, prepared to risk involvement in the drug trade, must understand the real potential for severe consequences. I acknowledge the prosecution concession as to the nature of the substances and the capacity for harm they involve as compared to other illicit substances in use in the community.

126. I must deal with a Commonwealth offence as part of this sentencing exercise and apply the provisions of Pt IB of the Crimes Act 1914. The sentence I impose must be of severity appropriate in all the circumstances: s 16A(1) of the Crimes Act 1914. I have taken into account those matters that are known and relevant pursuant to s 16A(2) of the Crimes Act 1914. With respect to the Commonwealth offence, whilst an unremarkable example of the offence, general deterrence is a consideration of some weight because “without significant penalties there are strong incentives for persons to refuse to comply” with the order: per Mossop J in R v White [2022] ACTSC 178 at [46].

127. I have considered the effect on the offender’s partner and adult son of any sentence imposed: s 33(1)(o) of the Crimes (Sentencing) Act. Hardship to an offender’s family need not be exceptional before it can be considered, though “it does not follow that the sentence must be reduced if family hardship is established”: see DPP v Moala (No 3) [2023] ACTSC 306 at [46]-[48] per McCallum CJ.

128. I readily accept, based on the evidence, that a sentence of full-time imprisonment will extinguish the day-to-day emotional support that the offender provides to his partner, which in the context of the challenges she experiences with respect to her diagnosed mental illness, will be a matter of real hardship for her. So too, her desire to start a family against the background of the fertility challenges she described.

129. The offender’s partner will experience a degree of financial hardship arising from the imposition of a period full time imprisonment and the consequent need for her to secure alternative accommodation and entirely bear household costs which the offender currently meets as part of their living arrangement. Whilst I accept this will be a trying circumstance for Ms Frank, I am not satisfied that she will be left without any option for accommodation as her evidence suggested. As Ms Morris’ report and Ms Frank’ payslips confirmed, Ms Frank is employed in the Australian Public Service at a level 6 and has a steady income. She has modest savings and will additionally realise any profit from the sale of the offender’s vehicle. The evidence does not permit a finding that it will be impossible for Ms Frank to obtain accommodation should the offender be sentenced to a period of full-time imprisonment. I accept her financial position will be altered given the offender’s significant contribution to the cost of their life together and that this represents some hardship for her.

130. The offender is present in his son’s life who looks to him for guidance and support. That relationship will necessarily be affected by the removal of the offender from the community.

131. I have also taken into account that the offender’s CPTSD symptoms will be exacerbated by the custodial environment and that he will experience custody more harshly than someone without CPTSD. I also accept that a full-time period of imprisonment will, at best, interrupt the substantial progress the offender has made toward rehabilitation in the period that he has been on bail.

132. Hardship to the offender’s loved ones and the interruption to the offender’s rehabilitation brought about by a sentence of full-time imprisonment, are regrettable consequences of the serious offending for which he must be held accountable. The hardship occasioned to the offender’s family is a matter that mitigates the appropriate sentence to a degree. But that consideration cannot be permitted to dilute or overwhelm the significance of the compelling sentencing considerations in this case to which I must have regard, general deterrence, denunciation, punishment and accountability. In this instance hardship to the offender’s family cannot justify service of any further period of imprisonment entirely in the community. Which is to say that I do not consider the period the offender spent in pre-sentence custody sufficiently reflects the purposes of sentencing nor would a suspended sentence or an ICO properly capture the gravity of the offending in light of the significance of the offender’s role. I note that an ICO would only be available if the sentence of imprisonment imposed was not more than 4 years.

133. The offender is to be sentenced for multiple offences which represent a course of conduct. There are also additional offences which must be taken into account. Whilst appropriately charged separately in relation to specific substances I am mindful of the need for the sentence to reflect the overall criminality of his conduct. I am also mindful of the need to guard against the perception that there is a discount for multiple offences and to ensure that the outcome is not ‘crushing’.

134. The Court of Appeal in R v White [2023] ACTCA 35 at [58] observed: Section 33(1)(c) of the Sentencing Act requires consideration of whether the offences form part of a course of conduct consisting of a series of criminal acts of the same or a similar character. Section 33(1)(c) recognises the “course of conduct” or “one transaction” principle, described by Owen JA in Royer v The State of Western Australia [2009] WASCA 139 at [22]: At its heart, the one transaction principle recognises that, where there is an interrelationship between the legal and factual elements of two or more offences with which an offender has been charged, care needs to be taken so that the offender is not punished twice (or more often) for what is essentially the same criminality. The interrelationship may be legal, in the sense that it arises from the elements of the crimes. It may also be factual, because of a temporal or geographical link or the presence of other circumstances compelling the conclusion that the crimes arise out of substantially the same act, omission or occurrences.

135. The task of assessing the “total criminality involved” involves consideration of factors which can pull in different directions. The Court of Appeal held in R v Carberry; R v Deng; Carberry v The King [2023] ACTCA 32 at [92]: There is no single correct approach to the structuring of multiple sentences, and the totality principle can be implemented in a variety of acceptable ways. In determining questions of accumulation or concurrence, his Honour was required to look at the totality of the criminal behaviour and consider whether the aggregate is “just and appropriate” for all the offences. A sentence should not be “crushing” in that it induces a sense of hopelessness and destroys prospects of rehabilitation, or too severe as a result or accumulation (noting the severity of a sentence may increase at a greater rate than the increase in its length). Against these considerations, a sentence should not lead to a perception that there is no difference between a person who commits one or two offences and a person who commits six or seven offences, or that an offender is being offered a discount for multiple offending. Making two counts wholly concurrent may reveal error in that to do so fails to take account of the differences in the conduct which were the subject of punishment on each count. (Citations omitted.)

136. In applying those principles, it is appropriate for the sentence imposed to involve a degree of concurrency, to ensure that the outcome reflects the overall criminality involved.

137. To give effect to the principle of totality the sentence for the Commonwealth offence will commence on the same day as the sentence for the first Territory offence.

138. A joint non-parole period cannot be imposed for the Territory and Commonwealth offences: s 19AJ of the Crimes Act 1914; Morrison v Maher [2021] ACTSC 312 at [49]. The most appropriate outcome in my view is to decline to make a recognizance order for Commonwealth offence (s 19AC of the Crimes Act 1914). I do so because on any view the more serious offences are the Territory offences and they will sufficiently ensure that the offender is supervised while on parole in the community. The non-parole period, which will apply only to the Territory offences, will begin on the commencement of the first Territory offence.

139. The prosecution conceded that the offender’s compelling subjective circumstances warrant the imposition of a non-parole period outside of what might be considered the ‘usual’ range. The non-parole period is the period that justice requires the offender to serve in custody, being the minimum period of actual incarceration having regard to the objective seriousness of the offending, the offender’s subjective circumstances, the purposes of sentencing including punishment, and the offender’s guarded prospect of rehabilitation. I agree that this is a matter where the non-parole can justifiably be outside the ‘usual’ range in recognition of the low risk. I am satisfied the offender presents to the community and the very real prospect of rehabilitation that he presents.

140. The starting point for count 1 (CAN2023/12129), supply anabolic steroids, is 30 months of imprisonment reduced to 1 year and 9 months of imprisonment in recognition of the plea of guilty and assistance to authorities.

141. The starting point for count 2 (CAN2023/12139), supply declared substance, is 24 months of imprisonment reduced to 1 year 4 months and 24 days of imprisonment in recognition of the plea of guilty and assistance to authorities.

142. The starting point for count 3 (CAN2023/12513), traffic in large commercial quantity of a controlled drug, namely psilocine, is 42 months of imprisonment reduced to 2 years 5 months and 11 days of imprisonment in recognition of the plea of guilty and assistance to authorities.

143. The starting point for count 4 (CAN2024/8066), traffic in large commercial quantity of a controlled drug, namely tetrahydrocannabinol (THC), is 36 months of imprisonment reduced to 2 years 1 month and 6 days of imprisonment in recognition of the plea of guilty and assistance to authorities.

144. The starting point for count 5 (CAN2024/12151), fail to comply with an order under s 3LA, is 12 months of imprisonment reduced to 8 months and 12 days of imprisonment in recognition of the plea of guilty and assistance to authorities.

Orders

145. The orders of the Court are: (1) On count 3 (CAN2023/12513) the offender is convicted and sentenced to 2 years, 5 months and 11 days of imprisonment commencing on 23 November 2025 and ending on 3 May 2028. (2) On count 4 (CAN2024/8066) the offender is convicted and sentenced to 2 years, 1 month and 6 days of imprisonment commencing on 28 March 2027 and ending on 3 May 2029. (3) On count 1 (CAN2023/12129) the offender is convicted and sentenced to 1 year and 9 months of imprisonment commencing on 4 June 2028 and expiring on 3 March 2030. (4) On count 2 (CAN2023/12139) the offender is convicted and sentenced to 1 year, 4 months and 24 days of imprisonment commencing on 11 June 2029 and expiring on 3 November 2030. (5) On count 5 (CAN2024/12151) the offender is convicted and sentenced to 8 months and 12 days of imprisonment commencing on 23 November 2025 and ending on 3 August 2026. (6) The total period of imprisonment is 4 years 11 months and 12 days commencing on 23 November 2025 and expiring on 3 November 2030. (7) I set a non-parole period for the Territory offences of 2 years and 3 months commencing on 23 November 2025 and expiring on 22 February 2028.

I certify that the preceding one hundred and forty-five [145] numbered paragraphs are a true copy of the Reasons for sentence of her Honour Justice Taylor. Associate: O Williams Date: 16 April 2026 Annexure A: list of packages seized on 14 November 2023

• A package addressed to [redacted] of Coolum QLD, containing a 10 ml vial of Durabol (Nandrolone Phenylproprate) 200mg and a 10 ml vial of T-entbolin (Testosterone Enanthate) 300 mg with sender details of [redacted]; • A package addressed to [redacted] of Surfers Paradise QLD, containing two 10 ml vials of T-entbolin (Testosterone Enanthate) 300 mg, with sender details of [redacted]; • A package addressed to [redacted] of Moranbah, QLD containing five 10 ml vials of Durabol (Nandrolone Phenylproprate) 200mg and five 10 ml vials of T-entbolin (Testosterone Enanthate) 300 mg, with sender details of [redacted]; • A package addressed to [redacted] of Diddillibah, QLD, containing three 10 ml vials of OzPharm Labs branded Test E 250 (Testosterone), with sender details of [redacted]; • A package addressed to [redacted] of Southport, QLD, containing two 10 ml vials of Sustanbolin 300mg (Testosterone), with sender details of [redacted]; • A package addressed to [redacted] of Kippa Ring, QLD, containing one box of 100 tablets of Stanobol 200mg and a box containing 100 tablets of Nexnos Pharma brand Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of South Mackay, QLD, containing a 10 ml vial of Sustanon 250 mg, a 10 ml vial of OzPharm Labs branded Parabolin (Trenbolone blend) 200mg and a box containing 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of Euramo, QLD, containing a 10 ml vial of OzPharm Labs branded Deca 250 mg (Nandrolone Decanoata) and a 10 ml vial of OzPharm Labs branded Sustanon 250 mg (Testosterone Sustanon), with sender details of [redacted]; • A package addressed to [redacted] of Broadbeach Waters, QLD, containing a 10 ml vial of OzPharm Labs branded Test E 250 mg and a box containing 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of Norman Gardens, QLD, containing three 10 ml vials of OzPharm Labs branded Test E 250 mg and a box containing 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, with sender details of [redacted]; • A package addressed to [redacted] of Karratha Western Australia, containing four 10 ml vials of Sustanon 250 mg (Testosterone Sustanon - OzPharm Labs brand), three 10 ml vials of Tren A 100 mg (Trenbolone Acetate - OzPharm Labs) and four vials of Deca 250 mg (Nandrolone Decanoata - OzPharm Labs brand), with a sender details of [redacted]; • A package addressed to [redacted] of Oakdowns, Tasmania, containing five bottles of 50 tablets of Pfizer brand Xanax 2mg (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of North Haven, NSW, containing eight 10 ml vials of OzPharm Labs branded Sustanon 250 mg (Testosterone Sustanon), a bottle containing 100 tablets of Nexnos Pharma branded Dianabol 100mg (Methandienone), a bottle containing 100 tablets of OzPharm labs branded Proviron 25 mg tablets, four 10mg vials of OzPharm Labs branded NPP 100mg (Nanadralone Phenylpropionate), three blister packs containing 10 Tamoxifen Citrate tablets and a box containing ten unlabelled vials with an unknown white substance inside each, with sender details of [redacted]; • A package addressed to [redacted] of Hunterview, NSW, containing two 10 ml vials of OzPharm Labs branded Test E 250 mg, six 10 ml vials of OzPharm Labs branded Test C 200mg (Testosterone Cypionate) and two 10 ml vials of OzPharm Labs branded Deca 250mg (Nandrolone Decanoata), with sender details of [redacted]; • A package addressed to [redacted] of Traralgone, Victoria, containing five boxes of 50 tablets of Valpam 5mg (diazepam 5mg), a box containing 50 tablets of Nexnos Pharma branded Armidex 2mg (Anastrozole) and two bags of High Society branded THC gummies, with a sender details of [redacted]; • A package addressed to [redacted] of Umina Beach, NSW, containing 15 packets, each weighing 60 grams, of PSI branded 'Cookies and Cream' flavoured psilocybine chocolates, with sender details of [redacted]; • A package addressed to [redacted] of Bodalla, NSW, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Hallett Cove, South Australia, containing two 10ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enanthate), with sender details of [redacted]; • A package addressed to [redacted] of Holt, NSW, containing two bottles of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Horsley, NSW, containing two 10 ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enanthate), with sender details of [redacted]; • A package addressed to [redacted] of Lara, Victoria, containing two boxes of 50 Nexnos Pharma branded Oxybol 50 mg tablets (Oxymetholone), with sender details of [redacted]; • A package addressed to [redacted] of Chadstone, Victoria, containing ten 10 ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enanthate), one box of 100 Nexnos Pharma branded Anavarabol 20mg tablets (Oxandrolone) and one bottle of 50 Nexnos Pharma branded Cialis 10mg tablets (Tadalafil), with sender details of [redacted]; • A package addressed to [redacted] of Bilambil Height, QLD, containing eight blister packs, each containing 10 Tapentadol Hydrochloride 200mg tablets, with sender details of [redacted]; • A package addressed to [redacted] of Umina Beach, NSW, containing 15 packets, each weighing 60 grams, of PSI branded 'Cookies and Cream' flavoured psilocybine chocolates, with sender details of "[redacted]"; • A package addressed to [redacted] of Bellebird Park, QLD, containing three 10 ml vials of Nexnos Pharma branded Sustanbolin 300mg (Testosterone Combination), with sender details of [redacted]; • A package addressed to [redacted] of Annerely, QLD, containing one 10 ml vial Nexnos Pharma branded T-entbolin 300 mg (Testosterone Enanthate) and one 10 ml vial of Nexnos Pharma branded Nandrolin 300mg (Nandrolone Decanoate), with sender details of [redacted]; • A package addressed to [redacted] of Nerang, QLD, containing three boxes of 100 tablets of Nexnos Pharma branded Clenbuterlin (Clenbuterol HCL) 40 mcg, one box of 100 Nexnos Pharma branded Anavarbol (Oxandrolone) 20 mg tablets, one 10 ml vial of Nexnos Pharma branded Primbolin 200 mg (Methenolone Enanthate), two 10 ml vials of Nexnos Pharma branded Durabol 200mg (Nandrolone Phenylpropiorate), one 10 ml vial of Nexnos Pharma branded Sustanbolin 300mg (Testosterone Combination), two 10 ml vials of Nexnos Pharma branded Parabolin-E 200 mg (Trenbolone Enanthate) and one bottle 100 OzPharm Labs branded Proviron 25mg tablets, with sender details of [redacted]; • A package addressed to [redacted] of Allambie Heights, NSW, containing one box of 50 Valpam 5mg tablets (Diazapam 5mg) with sender details of [redacted]; • A package addressed to [redacted] of Mascot, NSW, containing two 10 ml vials of OzPharm Labs branded Test E 250 mg (Testosterone Enaanthate), two 10 ml vials of OzPharm Labs branded Sustanon 250 mg(Testosterone Sustanon) and two 10 ml vials of OzPharm Labs branded Tren A 100 mg (Trenbolone Acetate), with a sender name of [redacted]; • A package addressed to [redacted] of Roxburgh Park, Victoria, containing a box containing 50 Clomiphene 20mg tablets and a bottle containing an unknown crystalline substance, with sender details of [redacted]; • A package addressed to [redacted] of Yarraville, Victoria, containing one 10ml vial of OzPharm Labs branded Test E 250 mg (Testosterone Enaanthate), one 10 ml vial of OzPharm Labs branded Mast E 200 mg (Drostanolone Enenthate) and one 10 ml vial of OzPharm Labs branded Masteron 100mg (Drostanolone Propionate), with sender details of [redacted]; • A package addressed to [redacted] of Carlingford, NSW, containing one bottle of 50 Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Kanimbla, Qld, containing one box of 50 Nexnos Pharma branded Oxybol 50 mg tablets (Oxymetholone), with sender details of [redacted]; • A package addressed to [redacted] of Port Macquarie, NSW, containing five bottles of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Launceston, Tasmania, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Capel, WA, containing three boxes of 100 Nexnos Pharma branded Anavarbol 20 mg tablets with sender details of [redacted]; • A package addressed to [redacted] of Randwick, NSW, containing a box of 100 Nexnos Pharma branded Anavarabol 20mg tablets (Oxandrolone) with sender details of [redacted]; • A package addressed to [redacted] of Hillside, Victoria, containing two 10 ml vials of OzPharm Labs branded Test C 200mg (Testosterone Cypionate), one 10 ml vial of OzPharm Labs branded Primobolan 100 mg (Methenolone Emanthate), two vials of Nexnos Pharma branded Fina 100mg (Trenbolone Acetate) and two 10 ml vials of Nexnos Pharma branded Banabolone (Boldenone Undercyclenate), with sender details of [redacted]; • A package addressed to [redacted] of Roxburth Park, Victoria, containing five 10 ml vials of OzPharm Labs branded Test E 250 mg, two 10 ml vials of OzPharm Labs branded Tren A 100 mg (Trenbolone Acetate), one 10 ml vial of OzPharm Labs branded Tren E 200 mg (Trenbolone Enanthate), two 10 ml vials of OzPharm Labs branded Test P (Testosterone Propionate), one 10 ml vial of Nexnos Pharma branded Durabol 200mg (Nandrolone Phenylpropiorate) and three blister packs containing 10 Tamoxifen Citrate tablets, with sender details of [redacted]; • A package addressed to [redacted] of Bendigo, Victoria, containing two bottles of 50 Xanax 2mg tablets (Alprazolam), with sender details of [redacted]; • A package addressed to [redacted] of Coomera, QLD, containing one vial of OzPharm Labs Test E 250 mg(Testosterone Enaanthate) and one 10 ml vial of OzPharm Labs branded Tren E 200 mg (Trenbolone Emanthate), with sender details of [redacted]; • A package addressed to [redacted] of Rockingham, WA, containing three 10 ml vials of Nexnos Pharma branded T-Entbolin 300mg (Testosterone Enanthate), with sender details of [redacted]. Annexure B: list of packages seized on 7 December 2023

• A package addressed to [redacted] of a Palm Beach Qld address, containing two 10 ml vials of OzPharmLabs branded Sustanon 250 (testosterone isocaproate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Drysdale Victoria address, containing two 10 ml vials of TEST E 250 (testosterone enanthate) and four OzPharmLabs branded MAST E 200 vials (drostanolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of an Alexandria NSW address, containing two 10 ml vials of Nexnos Pharma brand 300mg T-ENTBOLIN (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Pemulwuy NSW address, containing two 10 ml vials of OzPharmLabs branded TEST E 250 (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Malvern Victoria address, containing two blister packs of 10 tablets of Tadalafil 20mg and one 10 ml vial of Notorious Labs branded TREN (trenbolone) from sender [redacted], Broadbeach QLD; • A package addressed to [redacted] of a Maroochydore QLD address, containing a bottle of 30 NATCO branded Exemestane tables from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Towradgi NSW address, containing one bottle of Nexnos branded 100 Clenbuterlin tablets, two 10 ml vials of Nexnos branded T- ENTBOLIN 300 mg (testosterone enanthate) and one bottle of 100 OzPharmLabs branded Anavar 10mg tablets (oxandrolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Cardiff Heights NSW address, containing two 10 ml vials of OzPharmLabs branded TEST E 250mg (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Howes Creek Victoria address, containing two bottles of 50 tablets of Nexnos Pharma branded 10 mg Cialis Tadalafil from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of an Acacia Ridge QLD address, containing two 10 ml vials of OzPharmLabs branded Sustanon 250 mg (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Clayfield Qld address, containing two vials of OzPharmLabs branded TEST E 250 (testosterone enanthate) and one bottle of 50 Pfizer branded Xanax 2mg tablets (alprazolam) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Nerang Qld address, containing one bottle of 100 Nexnos branded Clenbuterlin tablets (Clenbeuterol), one 10 ml vial of OzPharmLabs branded DECA 250 (nandrolone decanoate) and one 10 ml vial of Nexnos branded T- ENTBOLIN 300 mg (testosterone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Nangor NSW address, containing four blister packs of 10 Fortune Health Care branded Tapentadol Hydrochloride 200 mg tabletsfrom sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Richmond NSW address, containing two blister packs of four Cabergoline .5mg tablets and a box of 30 Letrozole 2.5mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Teesdale Vicotria address, containing two vials of OzPharmLabs branded MAST E 250 MG (drostanolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Five Dock, NSW address, containing two bottles of 50 Nexons branded Oxybol 50mg tablets (oxymetholone), two bottles of 50 Nexons branded Clenbuterlin 40mcg tablets (Clenbeuterol) and two bottles of 100 Nexnos Pharma branded Dianabol 20mg tablets (methandrostenolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Milton Qld address, containing two 10 ml vials of Nexons branded Dihydroboldenone 100mg (synthetic testosterone), one 10 ml vial of OzPharmLabs branded TEST E 250mg(testosterone enanthate), one 10 ml vial of OzPharmLabs branded EQUIPOSE 250 (boldenone undecylenate), one 10ml vial of Nexons branded TEST 325 (testosterone blend) and two blister packs of 10 Tadafadil 20mg tablets from sender [redacted], Punchbowl NSW. • A package addressed to [redacted] of Mountain Creek Qld address, containing one 10 ml vial of OzPharmLabs branded TEST E 250 (testosterone enanthate), two 10 ml vials of OzPharmLabs branded DECA 250 (nandrolone decanoate) and one bottle of CBD oil from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of North Haen NSW address, containing five 10ml vials of OzPharmLabs branded SUSTANON 250 (testosterone isocaproate), five 10 ml vials of OzPharmLabs branded TEST E 250 (testosterone enanthate) one bottle of 100 Nexnos branded Dianabol 20mg tablets (methandrostenolone), one bottle of 100 OzPharmLabs branded PROVEN 25 mg tablets, one bottle of 50 OzPharmLabs branded ANAVAR 15 mg tablets (oxandrolone), ten vials of a white unknown substance and three blister packs of 10 Modafinil 200mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of Brighton LeSands address, containing three vials of OzPharmLabs branded SUSTANON 250 (testosterone isocaproate), three 10 ml vials of OzPharmLabs branded MAST E 250mg (drostanolone), one 10 ml vial of OzPharmLabs branded TEST E 250 (testosterone enanthate), two blister packs containing 10 Jeerima brand lsotretinon 20mg capsules, two Samanli brand 4 gram tubes of Oligopeptide powder and five blister packs containing 10 Tamoxifen 20mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] or Bunbury Western Australia address, containing one box of 50 Nexnos brand Tamoxifei Citrate (tamoxifen) 20 mg tablets, one bottle of 30 Exemestane tablets and a small vial of Human Chorionic Gonadotrophin (HCG) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Malabar NSW address, containing five 10 ml vials of OzPharmLabs brand SUSTANON 250 (testosterone isocaproate), five 10 ml vials of OzPharmLabs brand DECA250 (nandrolone decanoate) and one box of 500 Nexnos brand Tamoxfiei Citrate tablets (tamoxifen) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Sheffield Tasmania address, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (alprazolam) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Penrith NSW address, containing one bottle of 50 Pfizer Xanax 2mg tablets (alprazolam) from sender [redacted] Punchbowl NSW; • A package addressed to [redacted] of Leichhardt NSW address, containing one bottle of 50 Pfizer brand Xanax 2mg tablets (alprazolam) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Bellbird QLD address, containing three 10 ml vials of OzPharmLabs brand SUSTANON 250 (testosterone isocaproate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Muswelbrook NSW address, containing two 10 ml vials of OzPharmLabs brand TEST C 200 (testosterone cypionate) and one 10 ml vial of MAST E 200 (drostanolone) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Clyde North Victoria address, containing eight blister packs of ten Tapentadol Hydrochloride 200 mg tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Warners Bay NSW address, containing four 10 ml vials of Oz PharmLabs brand TEST E 250 (testosterone enanthate), four 10 ml vials of DECA 250 (nandrolone decanoate) and two 10 ml vials of TREN E 250 (trenbolone enanthate) from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a Bellpost Hill Victoria address, containing four 10 ml vials of OzPharmLabs brand TEST E 250 (testosterone enanthate) and one bottle of Nexnosbrand 100 Dianabol 20mg (methandrostenolone) tablets from sender [redacted], Punchbowl NSW; • A package addressed to [redacted] of a BundaII QLD address, containing nine 10 ml vials of MAST E 200 (drostanolone), two 10 ml vials of TEST E 250 (testosterone enanthate), five 10 ml vials of TEST P 100 (testosterone propionate), three 10 ml vials of NPP100 (nandralone phenylpropionate) and four boxes containing ten small vials of a white substance. Annexure C: list of substances seized on 8 December 2023

• 1X BOTTLE MOLNUVID 200MG 40 CAPSULES

• 3X VIALS OF MELANOTAN 10MG

• 1X BOX OF CLENBUTEROL 40MG (100 TABLETS)

• 1X BOTTLE ANAVAR 10 10MG

• 3X BLISTER PACK SHEETS "GMP" TABLETS (150 TABLETS)

• 4X ROLLS HEART SHAPED BRANDED TABLETS • 4X BLUE PILLS SILDENAFIL CITRATE

• 1X BLISTER PACK PAIN-O-SOMA 500MG (7 TABLETS)

• 2X BLISTERPACK TADALAFIL 20MG (8 TABLETS)

• 2X IGET KING VAPES • 1X BOTTLE DIANABOL 20MG (100 TABLETS) AND 1X BOTTLE CIALIS 10MG (SO TABLETS) • 1X BOTTLE CBD OIL "HIGH SOCIETY" 30ML

• 1X PACK HIGH SOCIETY THC GUMMYS

• 1X BOTTLE OF UNLABELLED LIQUID

• 1X SYRINGE WITH LIQUID RESIDUE

• 3X UNKNOWN TABLETS

• GMP UBLABELLED TABLETS BLISTER PAC

• SILDENAFIL CITRATE 100MG TABLETS X 7

• TAMOXIFAN CITRATE 20 MG X 100 TABLETS

• 9 X TABLETS TADALAFIL 20MG

• 1 X GREEN PLASTIC BOTTLE - UNLABELLED CAPSULES • 24 X BLISTER PACK OF PINK TABLET I 15 TAB EACH BLISTER WITH 10 MISSING - IBUPROFEN • 8 X WHITE BOXES CONTAINING 10 VIALS EACH - CONTAIN WHITE POWDER- UNKNOWN • 8 X BLISTER PACKS 15 X TABLETS PREGABALIN CAPSULES 300MG

• 1 X LARGE BAG WHITE/CREAM POWDERED SUBSTANCE & SPOON

• 3 X BLISTER PACKS 10 X TABLETS TADALAFIL 20MG

• 24 TABLETS OF VALPAM 5MG

• 100 X TABLETS OF STANOBOL

• 27 X TABLET OF LETROZOLE IP 2.5MG

• 6 X UNLABELED BOTTLES OF PILLS

• 2 X BOTTLES VYVANSE TABLETS

• 7 X VIALS OF MELANOTAN

• 2 X VIALS DIANABOL

• 9 X VIALS OF PENTADECAPEPTIDE

• 1 X BOX TAMOXIFEN CITRATE TABLETS

• 1 X BOTTLE MESTEROLONE TABLETS

• 12 X TAPENTADOL HYDROCHLORIDE TABLETS

• 1 X BOTTLE STANOBOL TABLETS

• 8 X VIALS MECHANO GROWTH FACTOR & 10 X VIALS BACTERIO STATIC WATER

• 1 X VIAL CLEAR LIQUID

• 4X VIALS WHITE POWDER

• 1 X BOTTLE S-23 SARM TABLETS

• 1 X BOX CATERGOLINE TABLETS

• 14 X TABLETS MESTEROLONE

• 6 X TABLETS DIAZAPAM

• 1 X CLIPSEAL BAG CONTAINING 8 X BLUE/PINK CAPSULES • 4 X TABLETS DICLOTENEE TABLETS

• 1 X BLUE TABLET

• 2 X BOTTLES SARM CARDARINE • 30 X SILDENAFIL CITRATE TABLETS

• 598X VIALS TEST BASE 75 CLEAR LIQUID

• 599X VIALS TEST BASE 75 CLEAR LIQUID

• 1600X NEXNOSTROPIN HUMAN GROWTH HORMONE VIALS

• 1610 X NEXNOSTRAPIN HUMAN GROWTH HORMONE

• 760 X NECNOSTROPIN HUMAN GROWTH HORMONE VIALS

• 122 X VIALS VIROME TESTOSTERONE

• 2 X BOTTLES ASPEN DEXAMFETAMINE

• 1 X BLISTERPACK CABERGOLINE 0.5MG

• 1 X BOTTLE THC OIL "QUATRO" BRAND 23MG

• 1 X BOTTLE ANTENEX 5 DIAZEPAM 5MG (9 TABLETS)

• 1 X BOTTLE MK677 IBUTAMORAN 5 CAPSULES 20MG

• 2 X BOTTLES "PURE NMN" (80 CAPSULES TOTAL) 250MG

• 1 X BOTTLE TUDCA (35 CAPSULES) 500MG

• 1 X BOTTLE "LIONS MAINE" 120ML

• 1 X BOTTLE "QUATTRO" CBD OIL

• 1 X BOTTLE HIGH SOCIETY CBD OIL

• 3 X BLISTERPACKS MESTEROLONE (28 TABLETS)

• 1 X PACK WATERMELON THC GUM MIES (lGUM)

• 1 X BOTTLE BPC 157 (34 TABLETS)

• 1 X TUB CONTAINING 1235 X VIALS MASTE-200 • 1 X TUB CONTAINING 1186 VIALS OF SUSTANON 250 TESTOSTERONE ISOCAPROATE

• 1 X TUB CONTAINING 665 VIALS DECANOATE 250 NANDROINE

• 1 X TUB 906 VIALS SUSTANON 250

• 1 X TUB 600 VIALS TRENE 200 • 1 X TUB 833 VIALS TRENBOLONE ACELATE 100MG

• 1 X TUB 474 BOXES (100 TABLETS EACH) CLENBUTERLIN HCL 40MG

• 1 X TUB 938 VIALS EQUIPOSE 250MG

• 1 X TUB 353 VIALS TEST P-100

• 1 X TUB 1020 VIALS MENT-50 200MG

• 1X TUB 164 BOXES TESTOSTERONE ETHERNATE

• 1X TUB 1207 BOXES MPP-100 100MG

• 1X CARDBOARD BOX 700 VIALS TEST-E 250

• 1X TUB 1366 VIALS TREN A100

• 1X CARDBOARD BOX 1000 VIALS TESTOSTERONE ENANTHATE 250MG

• 1X TUB 900 VIALS TEST-E

• 1X CARDBOARD 950 BOTTLES 250MG TEST-E

• 1X TUB 1278 BOTTLES MAST-E 200 DROSTABOLONE ENENTHATE

• 1X TUB 1099 BOXES MAST-E 200

• 315X PACKETS "HIGH SOCIETY" SOUR APPLE BLOSS BOMBS

• 1X TUB 1200 VIALS TRENBOLONE ENANTHATE 200MG

• 244X PACKETS HIGH SOCIETY THC GUMMIES (WATERMELON)

• 1X TUB 823 VIALS MASTERON - 100 AND 23 VIALS NPP

• 96X BOXES TESTOSTERONE PROPIONATE 100MG

• 291X BOXES TRENBOLONE ACTATE 100MG

• 1X TUB 308 NOTORIOUS LASBS TEST-E 250MG

• 1X TUB 85X BOXES NANDROLONE 100MG

• 1X TUB 128X NOTORIOUS LABS DECA-A 250MG • 1X TUB 200X BOXES MASTE 200MG

• 1X TUB 653X VIALS NOTORIOUS LABS TESTE

• 1X TUB 247X VIALS NOTORIOUS LABS TREN-E • 397X BOXES TESTOSTERONE 250ML

• 1X TUB 67X BOTTLES LIOTHYROIC - T3 25MG

• 1X TUB 545X BOTTLES ANAVA -10 10MG

• 1X TUB 83 BOTTLES OXYBOL OXYMETHOLONE 50MG

• 1X TUB 82 BOXES 10 VIALS EA PARABOLINE 200MG TRE

• 1X TUB 176 BOXES HALOTESTBOL 10MG

• 21 BOXES / 50 EA PROVIRANIC MESTEROLONE 25MG

• 1X TUB 98 VIALS MASTERBOLIN l00MG

• 175 BOXES NANDIOLIN 300MG

• 107 BOXES NANDIOLIN 300MG

• 55 BOXES ARMIDEXIC2MGX 50 TABLETS • 1X TUB 235 BOXES/ 50 EACH PROVIRONIC 25MG 100 BOXES /100 EACH TESTOSTERONE 200MG

• 1 TUB 54 BOXES/ 100 TABS EA. TESTOSTERONE 200MG

• 1X TUB - 110 BOXES - STANAINJECT 50MG

• 60 BOXES Ml TESBOL 5MG/50 TABS EACH

• 7 x BLISTER PACKS/ 10 EACH CLAMIFENE 50MG

• 106 BOXES/ 50 TABLETS EA 20MG CLORIPHEFEI

• 1X TUB 50 BOTTLES CLENBUTERLIN 40MG 100 TAB EA BOTTLE

• 128 BOXES/100 TABS X 20 MG STANOBOL • 146X 200MG DURABOL, 2X 300MG DURABOL 1X 100MG DURABOL 15X 150MG DURABOL

• 343X VIALS GANAOBOLONE 300MG

• 153 X PACKETS TAMOXIFEN CITRATE

• 270X VIALS PRIMBOLIN 200MG

• 21X VIALS T-PROBOUN 100-lO0MG • 206X VIALS VIROME l00MG

• 283X VIALS PARABOLIN 200MG

• 188X VIALS SUSTABOLIN TESTOSLERONE

• 51X BOXES SUSTEN-DEPO 10XlML PER BOX)

• 34 BOXES (10XlML DOSES) RX TEST 325

• 376X VIALS TEST-325 325MG

• 163 VIALS DIHYDROBOLDENEONE 100MG

• 168 VIALS MASTERBOLONE

• 1X BOX STANOBOL TABLETS

• 101X BOTTLES MENT-50 TRESTOSTELONE 50MG

• 177X DHB-100 lO0MG

• 322 X VIALS PARABOLIN - E 200MG

• 371 X VIALS SUPERBOLIN 50MG

• 127 VIALS TEST-E 250

• 252 X BOXES T-ENTBOLIN 300MG

• 108 X VIALS SUSTANON 250MG

• 304X VIALS TREN - A

• 233X BOXES EQUIPOSE 250MG

• 31 X VIALS DECA-250 250MG/10ML

• 513X VIALS MAST-E 200MG

• 192 X CIALS TREN-E 200MG

• 270 X VIALS NPD-100 100MG

• 397 X VIALS TREN-A 100MG • 184 X VIAL TEST-P 100MG

• 297X VIALS MASTERONE 100MG

• 194 X VIALS MAST-E 200MG • 322 X VIALS TEST-C 200MG

• 521 X VIALS PRIMOBOLAN 100MG

• 226 X VIALS TEST BASE 7SMG

• 237 X VIALS TEST BASE 7SMG

• 82 X BOTTLE PROVISION 25MG

• 242 X BOTTLES XANAX 2MG

• 187 X VIALS HCG 5000 IU

• 57 BOXES (10 VIALS PER BOX) HGH lSIU

• 137 X BLISTER PACK SILDENAFIL 100MG (10 PACKS)

• 162 X BLISTER PACKS TADALAFIL TABLETS 20MG

• 80 X VIALS NANDORLIN

• 83 X BOTTLES RAD-140 10MG

• 249 X BOTTLES KALMA 2MG

• 18 X VIALS 5-23 10MG

• 640 BLISTERPACKS (10 TABLETS EA) 200MG MODAFINIL

• 27 BOTTLES RAD-140 10MG

• 220 X VIALS GANABOLONE 300MG

• 74 x VIALS MASTERBOLIN 100MG

• 64 X VIALS TESTOSTERONE COMBINATION 300MG

• 108 X BOTTLES OSTARINE (60 TABLETS) 10MG

• 416 X BOXES SARMS - OSTARI - BOL (50 PER BOX) 10MG

• 88 X BOTTLES OSTARINE (60 TABLETS EA) 10MG

• 102 X VIALS SARMS - OSTARI - BOL 10MG (SO PER BOX) • 15 BOXES OLIGOPEPTIDE IYOPHILIZED POWDER (80 PER BOX)

• 74 X BOTTLES GW 501516 (60 TABLETS EA)

• 657 BLISTERPACKS (lOEA) TYPENTA 200 MG • 68 BLISTERPACKS (lOEA) TAPADAY 200MG

• 50 BOTTLES MK677 10MG (60 TABLETS EA)

• 452 BLISTERPACKS (lSEA) TELMISARTHEN 40MG

• 85 X BOXES (30 EA) FEMARIC 28MG

• 1901X BLISTERPACKS (lOEA) TAMOXIFEN-CITRATE 20MG

• 3 X VIALS DROSTANOLONE ENENTHATE 200MG (10ML PER VIAL)

• 1 X ARMODAFINIL TABLETS

• 999 OZPHARMLABS TEST E

• 14 BOXES OF LIFTHENG SOX BOXES OF NPP100

• SAMAULI BOXES, OLIGOPETIDE 4G X 20 22 X QUATTRO THC OIL

• 502 X TREN E200

• 411 X DECA 250

• 200 x SUSTANON 250

• 15 X 50 + 1 X 35 BOXES MAST E 250

• SUSTANON 250 X 1000 BOXES

• 5 BOXES PEARL POWDER & CONTENTS

• 2 X BOTTLES EXEMESTANE 25MG X 30

• 3 X BOTTLES CIALIS LONG X SO TABS

• 18 X QUATTRO THC OIL

• SUSTANON 250 (16X50) (1X50) (1X47) (1X34) BOXES

• 6 X BOXES OLIGOPEPTIDE SUS

• 28 SAMANLI 4G X 20

• 20 X BAGS SUSTANON (19X50) (1X47) • 1 X BOX TASALAFIL TABLETS 20MG

• 1 X VIAL WINSTROBOLIN 50 TABS

• CIALIS LONG X 50 TABS X 518 BOTTLES • PARABOLAN 200MG X 24 BOXES

• TEST E 250 - 1120 BOXES

• TRENA 100 (12X50) (1X35) BOXES

• 2 X BOXES DAMASCUS ROSE HYDROSOL

• 6 X LYOPHILIZED POWDER (BOXES) TREN E 200 - 50 BOXES

• PSI CHOCOLATE - 30 BLOCKS

• NPP100 - 20 BAGS X 50 BOXES EPC157 - 59 BOXES

• SUSTANON 250 - 247 BOXES

• TEST E 250 - 432 BOXES • TRENA 100 - 400 BOXES LIFEHEAVY ICE MASKS - 2 BOXES QUATTRO CBD OIL X 20

• TEST 325 - 232 BOXES

• 3 X BPC 157 I 2 VIALS NEXNOSTROPIN I 1 UNLABLLED VIAL

• 5 EPIPENS

• TREN E 200 - 774 BOXES

• 1 QUATTRO CBD OIL

• 1 HIGH SOCIETY CANNABIS VAPE

• 2 BLISTER PACKS OF LETROHEAL 2.5MG • 10 X 1ML EPIPENS I 1.5ML EPI PEN I 6 TOBLERONE CHOCOLATE SIKMAFAL CITRATE - 2200 TABS

• TEPENTADOL 200MG - 286 PACKETS TEST P 200 - 375 BOXES

• SUSTANBOLIM 300 MG - 1 BOX

• OMNITROWLE

• 20 UNLABELLED BOXES I 13 UNLABELLED BOTTLES

• 5 X CBD OIL BOTTLES

• DIANABOL 20MG - 100 TABLETS • 1 X KALMA 2MG BOTTLE

• 1 BOX LEROZOLE 2.5MG

• 1 CBD OIL VAPE

• LEVOTHYROXIME - 39 BOXES (100 TABLETS PER BOX)

• 19 CBD OIL BOTTLES

• LIOTHYRONINE SODIUM - 49 BOXES

• SILDENAFIL CITRATE 100MG TABLETS (BLISTER PACKET OPEN)

• CIALIS 10MG - 1 BOTTLE

• NPP 100 - 475 BOXES

• 4 BLISTER PACKS VIDALISTA

• 9 BOTTLES ANADRORAL

• 50 BOXES OF 100 EUTHYROX 50

• 1 BOX CLOMIFENE CITRATE 30 TABLETS

• 4440 X CLOMIFENE CITRATE

• 77 BOXES HIGHLY PURIFIED CLORIONIC GONADOTROPHIY

• 110 BLISTER PACKS OF CAVBISET TABS

• 461 OXYBOL NUMEROUS STEROIDS

• 42 BOXES CHORION IC GONADOTTROPIN

• 92 QUATTRO CBD

• 230 ANASTROZOTE 1MG TABS

• 1 BOX ISOTRETINOIN CAPS, 30MG

• 231 BLISTER PACKS OF ISOTRETINOIN CAPSULES

• 2 MELANOTAN 2 (10MG) • 9 MGF 5MG

• BZ 15 X IGFI (1MG) 25 HEXARELIN

• 16 GLYCIPHASE 850 • 2 ARMIDEXIC 2MG X 50 TABLETS

• 114 PROVIRONUM BLISTER PACKS

• 208 BLISTER PACKS OF ANASTROZOLE TABS 1MG

• 695 TABS OF PRESABALIN 300MG

• 300 TABS ZOPICLON 20MG

• 9370 TABS OF TAMOXIFEN CITRATE

• 39 BLISTER PACKS OF VARIOUS SUBSTANCES

• 98 BLISTER PACKS OF FLIBAN

• TAMOTIFEN - 9 BLISTER PACKS

• 1 GREEN BOTTLE OF CAPSULES

• TADALAFIL 20MG - 9 BLISTER PACKS

• ANASTROZOLE 1MG - 12

• PSI CHOCOLATE -10 BLOCKS

• 449 BOXES OF FEWTBOLIN 300MG

• ASSORTED VIALS, BLISTER PACKS

• 492 BOTTLES XANAX

• NUMEOUS STEROID ITEMS

• 1560 TABS RALOXIHEAD 60MG

• 50 TABS CLONIFENE TABS

• 14 X 10 BLISTER PACKS CORISPRODOL

• 20 VIALS OF PENTADELAPEPTIDE

• VARIOUS SUBSTANCES

• 134 GREEN BOTTLES CONTAINING CAPSULES • 180 TAMOXIFEI, 50 X NEXOS

• 1001 TREN-A 100

• 2490 TABLETS OF CETROZOLE 2.5MG • 1 VIAL HEXARELIU SMG

• VARIOUS SUBSTANCES

• 208 CONTAINERS OF NUMEROUS STERIODS (50 TABS EACH)

• 10 BLISTER PACKS ZOPICLANE 20MG

• 1 X CLIPSEAL BAG CONTAINING ASSORTED VIALS

• VARIOUS STEROIDS

• 2 X VAPES

• 10 VIALS MASTERBOLENE 10 ML

• 41 VIALS OF MASTERBOLONE 10ML

• OPEN HIGH SOCIETY THC GUMMIES

• FLIBAMSERIN 100MG OPEN BLISTER PACK

• 17 VIALS OF HIGH SOCIETY CBD OIL

• 7 UNLABELLED VIALS OF LIQUID

• 1 VIAL OF TEST 325

• 1 BOX CABERGOLINE C18 TABS

• 1 BOTTLE OF DIAUABORAL

• 1 BOTTLE OF Ml TESBOL

• 1 VIAL OF EQUIPOLE 250

• 1 VIAL TREN-A

• 12 X BOXES + 47 BOTTLE OF EXENESTON

• 146 X 4 BLISTER PACKS OF CABERGOLONE CABERDOST O.SM

• 100 BLISTER PACKS ASTROZOLE TABLETS

• 410 BOXES CONTAINING 10 VIALS OF UNKNOWN SUBSTANCE • 135 HIGH SOCIETY VANILLA CANNABIS VAPES

• 60 PACKS OF PENTADECA-PEPTIDE 5MG VIALS

• 100 BLISTER PACKS ANASTROZOLE • 10 X 4 BLISTER PACKS CABERGOLINE CABGOLIU 0.5MG

• 220 X 4 BLISTER PACKS OF CABERGOLINE DOSTILHEAL 0.5MG

• 1 BLISTER PACK OF PREGABOLIN

• LIOTHROIC/T3 X 330 BOTTLES & LIOTHYROIC SODIUM X 25 BOTTLES

• STANOBOL X 150 BOXES

• 140 DIANABOL X 473 BOTTLES

• RX TEST 325 X 48 BOXES

• 24 BOXES OF UNKNOWN WHITE POWDER

• 24 BOXES OF UNKNOWN WHITE POWDER

• 1017 BLISTER PACKS+ 10 BOXES OF ARASTROZOLE

• 4 HIGH SOCIETY RELIEF CBD OILS

• 119 VAPE PENS

• 806 VIALS WITH YELLOW LIDS CONTAINING UNKNOWN SUBSTANCES

• 2350 VIALS OF UNKNOWN SUBSTANCE IN FOIL

• 60 BOXES OF PENTADECAEEPTIDE B 5MG

• 10 VIALS OF PROGONALZOOP

• 19 BAGS - 50 TEST E

• 2 X CLIP SEAL BAGS OF BROWN POWDER

• 1 X CLIP SEAL BAG OF YELLOW CRYSTALLINE SUBSTANCE

• 1 X UNLABELLED BOTTLE CONTAINING LIQUID